BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,080 filers reported holding BAXTER INTL INC in Q3 2020. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $40,328,964 | +13.2% | 1,068,600 | +36.7% | 0.81% | +15.6% |
| Q2 2023 | $35,618,125 | +3.7% | 781,785 | -7.7% | 0.70% | -10.0% |
| Q1 2023 | $34,343,166 | +110.7% | 846,725 | +164.7% | 0.78% | +106.1% |
| Q4 2022 | $16,303,213 | +7.4% | 319,859 | +13.5% | 0.38% | -5.2% |
| Q3 2022 | $15,182,000 | +14.0% | 281,875 | +36.0% | 0.40% | +24.2% |
| Q2 2022 | $13,316,000 | -25.1% | 207,316 | -9.5% | 0.32% | -16.6% |
| Q1 2022 | $17,767,000 | -5.9% | 229,136 | +4.2% | 0.39% | -5.4% |
| Q4 2021 | $18,881,000 | +8.7% | 219,957 | +1.8% | 0.41% | +1.5% |
| Q3 2021 | $17,373,000 | +10.2% | 215,997 | +10.3% | 0.40% | +10.4% |
| Q2 2021 | $15,770,000 | +18.1% | 195,902 | +23.8% | 0.36% | -0.5% |
| Q1 2021 | $13,348,000 | +6.9% | 158,269 | +1.7% | 0.37% | -12.6% |
| Q4 2020 | $12,490,000 | +0.9% | 155,654 | +1.1% | 0.42% | -14.7% |
| Q3 2020 | $12,383,000 | +19.9% | 153,977 | +28.4% | 0.49% | +15.5% |
| Q2 2020 | $10,326,000 | +42.9% | 119,930 | +34.8% | 0.42% | +12.4% |
| Q1 2020 | $7,226,000 | -2.9% | 89,000 | 0.0% | 0.38% | +28.6% |
| Q4 2019 | $7,442,000 | +742.8% | 89,000 | +781.2% | 0.29% | +740.0% |
| Q3 2019 | $883,000 | +21.1% | 10,100 | +13.5% | 0.04% | +29.6% |
| Q2 2019 | $729,000 | +0.7% | 8,900 | 0.0% | 0.03% | +8.0% |
| Q1 2019 | $724,000 | +23.5% | 8,900 | 0.0% | 0.02% | +19.0% |
| Q4 2018 | $586,000 | -28.9% | 8,900 | -16.7% | 0.02% | -8.7% |
| Q3 2018 | $824,000 | +25.4% | 10,686 | +20.1% | 0.02% | +21.1% |
| Q2 2018 | $657,000 | +13.5% | 8,900 | 0.0% | 0.02% | +11.8% |
| Q1 2018 | $579,000 | +0.7% | 8,900 | 0.0% | 0.02% | +6.2% |
| Q4 2017 | $575,000 | -19.4% | 8,900 | -21.8% | 0.02% | -20.0% |
| Q3 2017 | $713,000 | +3.5% | 11,375 | 0.0% | 0.02% | +5.3% |
| Q2 2017 | $689,000 | +14.1% | 11,375 | -2.3% | 0.02% | +18.8% |
| Q1 2017 | $604,000 | +19.6% | 11,640 | +2.3% | 0.02% | +14.3% |
| Q4 2016 | $505,000 | -6.7% | 11,375 | 0.0% | 0.01% | -12.5% |
| Q3 2016 | $541,000 | +11.1% | 11,375 | +5.7% | 0.02% | 0.0% |
| Q2 2016 | $487,000 | +10.2% | 10,760 | 0.0% | 0.02% | +14.3% |
| Q1 2016 | $442,000 | +30.0% | 10,760 | +20.9% | 0.01% | +55.6% |
| Q4 2015 | $340,000 | +151.9% | 8,900 | +117.1% | 0.01% | +200.0% |
| Q3 2015 | $135,000 | -51.8% | 4,100 | +2.5% | 0.00% | -50.0% |
| Q2 2015 | $280,000 | – | 4,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |